Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Mona KafkaThomas BurtscherJosef FritzMaximilian SchmitzJasmin BekticMichael LadurnerWolfgang HorningerIsabel HeideggerPublished in: World journal of urology (2022)
We observed a trend towards a higher benefit of NHT as first-line treatment compared to Docetaxel in men with mHSPC. Of note, a PSA-Nadir ≤ 0.05 ng/ml or a TSH-increase during therapy were predictors for therapy response.